Kiang, Joan T
Jonas, A
Disclosures: Eun-Jung Kim: Nothing to Disclose, Dasol Kim: Nothing to Disclose, Banu Akdogan: Nothing to Disclose, Mikkel Holm Vendelbo: Nothing to Disclose, Emilie Munk: Nothing to Disclose, Judith Sailer: Nothing to Disclose, Adriana Filipa Fontes: Nothing to Disclose, Jonas Engler: Nothing to Disclose, Dongsik Park: Nothing to Disclose, Hongjae Lee: Nothing to Disclose, Chunwon Jung: Nothing to Disclose, Byong-Keol Min: Nothing to Disclose, Eok Park: Nothing to Disclose, TaeWon Kim: Nothing to Disclose, Seoyoung Choi: Nothing to Disclose, So-yeon Kim: Nothing to Disclose, Alan DiSpirito: Nothing to Disclose, Thomas Sandahl: Arbormed: Advisor, Orphalan: Speaking and Teaching, Alexion: Grant/Research Support, Univar: Consultant, Ultragenyx: Advisor, Weonbin Im: Nothing to Disclose, So-Young Eun: Nothing to Disclose, Hans Zischka: ArborMed Co., Ltd: Consultant, Valentina Medici: Orphalan: Advisor, Arbormed: Research Grant, Ultragenix: Research Grant, Alexion: Advisor, Vivet: Grant/Research Support 2634 THE IFN-INDUCIBLE MXB LARGE GTPASE ATTENUATES HBV REPLICATION BY ACTIVATING THE RIG-I INNATE IMMUNITY SIGNALING PATHWAY Masazumi Onuki 1 Jun Inoue 1 Masashi Ninomiya 1 Mio Tsuruoka 1 Kosuke Sato 1 Satoko Sawahashi 1 Keishi Ouchi 1 Kengo Watanabe 1 Mark McNiven 2 Atsushi Masamune 1 , 1 Tohoku University Graduate School of Med, 2 Mayo Foundation for Medical Background: Elimination of hepatitis B virus (HBV) from chronically infected patients remains difficult, even though nucleos(t)ide analogs, potent inhibitors of reverse transcription, are widely available
Measured mass isotopologues distributions expressed as mol percent were corrected for natural enrichment 59,64
